Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ofatumumab as Part of the Reduced Intensity Conditioning Regimen for Patients With High Risk Chronic Lymphocytic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation: a Pilot Study by GETH and GELLC

NCT01455051 is registered in ClinicalTrials.gov with Grupo Espanol de trasplantes hematopoyeticos y terapia celular as lead sponsor.

NCT NCT01455051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01455051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ofatumumab as Part of the Reduced Intensity Conditioning Regimen for Patients With High Risk Chronic Lymphocytic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation: a Pilot Study by GETH and GELLC
Lead sponsor
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
October 31, 2017
Enrollment
25 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia